SCHEMBL148106

SCHEMBL148106

O=C(O)c1cccc2c(Br)cccc12

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRNP P04156 1/20 0.76
KMT2A Q03164 8/20 0.61
MEN1 O00255 7/20 0.61
NR4A1 P22736 1/20 0.57
NR4A2 P43354 1/20 0.57
NR4A3 Q92570 1/20 0.57
ALDH1A1 P00352 2/20 0.48
ALOX15 P16050 1/20 0.48
AHR P35869 1/20 0.47
CDC25B P30305 1/20 0.46
FABP4 P15090 1/20 0.45
PTPN1 P18031 1/20 0.44
RXFP1 Q9HBX9 1/20 0.43
KDM4E B2RXH2 1/20 0.42
CYP2C9 P11712 1/20 0.42
HPGD P15428 1/20 0.42
TSHR P16473 1/20 0.42
ALOX12 P18054 1/20 0.42
ATIC P31939 1/20 0.42
HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6913251 0.98 PRNP (0.73) PRNPKMT2AMEN1NR4A1NR4A2
SCHEMBL6915323 0.98 PRNP (0.73) PRNPKMT2AMEN1NR4A1NR4A2
SCHEMBL6915637 0.98 PRNP (0.73) PRNPKMT2AMEN1NR4A1NR4A2
SCHEMBL6913620 0.98 PRNP (0.73) PRNPKMT2AMEN1NR4A1NR4A2
SCHEMBL6913244 0.98 PRNP (0.73) PRNPKMT2AMEN1NR4A1NR4A2
SCHEMBL6913860 0.98 PRNP (0.73) PRNPKMT2AMEN1NR4A1NR4A2
SCHEMBL6913857 0.98 PRNP (0.73) PRNPKMT2AMEN1NR4A1NR4A2
SCHEMBL6916189 0.98 PRNP (0.73) PRNPKMT2AMEN1NR4A1NR4A2
SCHEMBL6913618 0.98 PRNP (0.73) PRNPKMT2AMEN1NR4A1NR4A2
Hydrochloric Acid SCHEMBL11734513 0.98 PRNP (0.73) PRNPKMT2AMEN1NR4A1NR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112945912-B High-brightness large-Stokes-shift wash-free lipid-droplet fluorescent probe and synthetic method and application thereof 中国科学院大连化学物理研究所 2023-02-21 CN claimed
CN-112945912-A High-brightness large-Stokes-shift wash-free lipid-droplet fluorescent probe and synthetic method and application thereof 中国科学院大连化学物理研究所 2021-06-11 CN claimed
CN-109134371-B Fluorescence ratio probe, synthetic method thereof and application of fluorescence ratio probe in detecting intracellular lysosome formaldehyde 东北大学 2020-07-10 CN claimed
EP-4652154-A1 NOVEL ALPK1 INHIBITORS Pyrotech (Beijing) Biotechnology Co., Ltd. (CN) 2025-11-26 EP disclosed
US-20250345446-A1 BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES DRAUPNIR BIO APS (DK) 2025-11-13 US disclosed
US-20250289812-A1 COMPOUND FOR TREATING THROMBOTIC DISEASES RUIJIN HOSPITAL, SHANGHAI JIAOTONG UNIVERSITY SCHOOL OF MEDICINE (CN) 2025-09-18 US disclosed
US-12378224-B2 Heteroaryl compounds and their use as Mer inhibitors DONG-A SOCIO HOLDINGS CO., LTD. (KR) 2025-08-05 US disclosed
EP-4565121-A1 CARBON MONOXIDE PROBE MOLECULES Georgia State University Research Foundation, Inc. (US) 2025-06-11 EP disclosed
CN-119997870-A Carbon monoxide probe molecule 乔治亚州立大学研究基金会股份有限公司 2025-05-13 CN disclosed
EP-4543858-A1 BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES Draupnir Bio ApS (DK) 2025-04-30 EP disclosed
WO-2024153225-A1 NOVEL ALPK1 INHIBITORS PYROTECH (BEIJING) BIOTECHNOLOGY CO., LTD. (CN) 2024-07-25 WO disclosed
US-4946987-A Treatment for complications of diabetes AYERST, MCKENNA & HARRISON, INC. (CA) 1990-08-07 US disclosed
US-4705882-A ALDOSE REDUCTASE INHIBITORS, ANTIDIABETIC AGENTS AYERST, MCKENNA & HARRISON, INC. (CA) 1987-11-10 US disclosed
US-4600724-A ALDOSE REDUCTASE INHIBITOR, DIABETES AYERST, MCKENNA & HARRISON, INC. (CA) 1986-07-15 US disclosed
US-4568693-A ANTIDIATBETIC AGENTS AYERST, MCKENNA & HARRISON, INC. (CA) 1986-02-04 US disclosed
EP-0059596-B1 N-NAPHTHOYLGLYCINE DERIVATIVES AYERST, MCKENNA AND HARRISON INC. (CA) 1985-04-24 EP disclosed
US-4439617-A TREATING DIABETES, ENZYME INHIBITOR AYERST, MCKENNA & HARRISON INC. (CA) 1984-03-27 US disclosed
US-4391816-A ANTIDIABETIC AGENTS AYERST, MCKENNA & HARRISON INC. (CA) 1983-07-05 US disclosed
EP-0059596-A1 N-Naphthoylglycine derivatives AYERST, MCKENNA AND HARRISON INC. (CA) 1982-09-08 EP disclosed
US-3980667-A Anti-arrhythmic 5-endo-substituted oxy-N-(aminoloweralkyl)bicycle [2.2.2.]oc BRISTOL-MYERS COMPANY (US) 1976-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250289812-A1 COMPOUND FOR TREATING THROMBOTIC DISEASES ITGB3, SRC, FYN PRNP 1761/4885KMT2A 4193/4885MEN1 3939/4885
US-12378224-B2 Heteroaryl compounds and their use as Mer inhibitors MERTK, RET, ERBB2 PRNP 424/4885KMT2A 2442/4885MEN1 379/4885
US-20250345446-A1 BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES SORT1, SCARB1, LAMP1 PRNP 2740/4885KMT2A 4557/4885MEN1 2813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.